2020-10-20

1: Elsheikh W, Blackler RW, Flannigan KL, Wallace JL. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide. 2014 Apr 18. pii: S1089-8603(14)00204-3. doi: 10.1016/j.niox.2014.04.006. [Epub ahead of print] PubMed PMID: 24747869.

2: Ekundi-Valentim E, Mesquita FP, Santos KT, de Paula MA, Florenzano J, Zanoni CI, Rodrigues L, de Nucci G, Teixeira SA, Ferreira HH, Wallace JL, Costa SK, Muscará MN. A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Med Gas Res. 2013 Nov 16;3(1):24. doi: 10.1186/2045-9912-3-24. PubMed PMID: 24237604; PubMed Central PMCID: PMC3843537.

3: Campolo M, Esposito E, Ahmad A, Di Paola R, Wallace JL, Cuzzocrea S. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB J. 2013 Nov;27(11):4489-99. doi: 10.1096/fj.13-234716. Epub 2013 Jul 30. PubMed PMID: 23901068.

4: Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012;7(4):e35196. doi: 10.1371/journal.pone.0035196. Epub 2012 Apr 9. PubMed PMID: 22496907; PubMed Central PMCID: PMC3322164.

5: Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010 Mar;159(6):1236-46. doi: 10.1111/j.1476-5381.2009.00611.x. Epub 2010 Feb 1. PubMed PMID: 20128814; PubMed Central PMCID: PMC2848928.